Vizz Is FDA-Approved
Blog Entry – July 31, 2025
Introducing Vizz: New Daily Eye Drop for Blurry Near Vision (Presbyopia)
If you’re one of the many people over 45 struggling to read small print, use smartphones comfortably, or see up close without holding items at arm’s length—you’re in good company. Fortunately, there’s promising news: Vizz (aceclidine ophthalmic solution 1.44 %) is now FDA-approved for the treatment of presbyopia in adults, offering a potential game-changer for near-vision clarity. (Medscape)
📊 Trial Snapshot
Vizz’s approval was built on three randomized, double-masked Phase 3 trials—named CLARITY 1, 2 and 3—conducted by LENZ Therapeutics.
CLARITY 1 and 2 enrolled 466 adults with presbyopia, treated once-daily for 42 days. (WebMD)
CLARITY 3 enrolled 217 adults for long-term safety over six months of daily dosing. (Medical Xpress)
Altogether, more than 30,000 treatment days of data were submitted. (Drugs.com)
🧪 Methods
Participants were administered one drop of Vizz once daily (in each eye, a second drop two minutes later per prescribing information) and compared with control treatments (placebo or alternate drop) in masked fashion. Near‐vision acuity was measured at multiple time-points (30 minutes, several hours, up to 10 hours) to assess onset and duration of effect. Importantly, distance vision was monitored to ensure it was not compromised. (WebMD)
✅ Key Results
Rapid onset: Within 30 minutes, approximately 65 %–71 % of Vizz users achieved a ≥3-line improvement in near visual acuity without losing a line of distance vision. In CLARITY 1: 65 % vs ~12 % in control; in CLARITY 2: 71 % vs ~8 %. (WebMD)
Duration: In both trials, up to 40 % of participants maintained improved near vision after 10 hours of dosing. (WebMD)
Distance vision preserved: No meaningful reduction in distance acuity was observed.
Long-term data: In the six-month safety trial, no new concerns emerged.
⚠️ Safety & Side Effects
The safety profile of Vizz was favorable. No serious treatment-related adverse events were reported across all three trials. (Medical Xpress) The most commonly reported side-effects included:
Instillation-site irritation (≈20 %)
Dim vision (≈16 %)
Headache (≈13 %)
Conjunctival hyperemia (≈8 %)
Ocular hyperemia (≈7 %) (LENZ Therapeutics, Inc.)
Most events were mild, transient and resolved without intervention. However, the prescribing information highlights the need for baseline retinal examination, as there is a rare risk of retinal tear/detachment with miotic agents. (FDA Access Data)
📝 Conclusions
For adults dealing with age-related blurry near vision, Vizz represents an important new option. The once-daily drop offers rapid onset of improvement, meaningful duration (up to 10 hours), and a strong safety profile. Since its approval, Vizz promises greater flexibility and fewer reliance on reading glasses for many patients.
As always, a discussion with your eye-care provider remains essential to determine if Vizz fits your individual vision needs and health status.
Stay tuned for availability in U.S. pharmacies (anticipated fall 2025) and ask our practice how you can get started.
This blog entry is for informational purposes only and does not replace an eye-care consultation. Always follow the prescribing information and advice of your physician.
